Descriptive analysis of long COVID sequelae identified in a multidisciplinary clinic serving hospitalised and non-hospitalised patients.
Journal
ERJ open research
ISSN: 2312-0541
Titre abrégé: ERJ Open Res
Pays: England
ID NLM: 101671641
Informations de publication
Date de publication:
Jul 2021
Jul 2021
Historique:
received:
20
03
2021
accepted:
20
04
2021
entrez:
4
8
2021
pubmed:
5
8
2021
medline:
5
8
2021
Statut:
epublish
Résumé
There are emerging data of long-term effects of coronavirus disease 2019 (COVID-19) comprising a diversity of symptoms. The aim of this study was to systematically describe and measure pulmonary and extra-pulmonary post-COVID-19 complications in relation to acute COVID-19 severity. Patients attending a standard of care 3 months post-hospitalisation follow-up visit and those referred by their general practitioner because of persistent post-COVID-19 symptoms were included. Patients underwent symptomatic, quality of life, pulmonary (lung function and high-resolution computed tomography (HRCT)), cardiac (high-resolution ECG), physical (1-min sit and stand test (1-MSTST), handgrip strength, cardiopulmonary exercise testing (CPET)) and cognitive evaluations. All 34 hospitalised and 22 out of 23 non-hospitalised patients had ≥1 complaint or abnormal finding at follow-up. Overall, 67% of patients were symptomatic (Medical Research Council (MRC) ≥2 or COPD assessment test (CAT) ≥10), with no difference between hospitalised Three months after COVID-19 infection, patients were still symptomatic and demonstrated objective respiratory, functional, radiological and cognitive abnormalities, which were more prominent in hospitalised patients. Our study underlines the importance of multidimensional management strategies in these patients.
Sections du résumé
BACKGROUND
BACKGROUND
There are emerging data of long-term effects of coronavirus disease 2019 (COVID-19) comprising a diversity of symptoms. The aim of this study was to systematically describe and measure pulmonary and extra-pulmonary post-COVID-19 complications in relation to acute COVID-19 severity.
METHODS
METHODS
Patients attending a standard of care 3 months post-hospitalisation follow-up visit and those referred by their general practitioner because of persistent post-COVID-19 symptoms were included. Patients underwent symptomatic, quality of life, pulmonary (lung function and high-resolution computed tomography (HRCT)), cardiac (high-resolution ECG), physical (1-min sit and stand test (1-MSTST), handgrip strength, cardiopulmonary exercise testing (CPET)) and cognitive evaluations.
RESULTS
RESULTS
All 34 hospitalised and 22 out of 23 non-hospitalised patients had ≥1 complaint or abnormal finding at follow-up. Overall, 67% of patients were symptomatic (Medical Research Council (MRC) ≥2 or COPD assessment test (CAT) ≥10), with no difference between hospitalised
CONCLUSION
CONCLUSIONS
Three months after COVID-19 infection, patients were still symptomatic and demonstrated objective respiratory, functional, radiological and cognitive abnormalities, which were more prominent in hospitalised patients. Our study underlines the importance of multidimensional management strategies in these patients.
Identifiants
pubmed: 34345629
doi: 10.1183/23120541.00205-2021
pii: 00205-2021
pmc: PMC8091683
pii:
doi:
Types de publication
Journal Article
Langues
eng
Informations de copyright
Copyright ©The authors 2021.
Déclaration de conflit d'intérêts
Conflict of interest: S. Johnsen has nothing to disclose. Conflict of interest: S.M. Sattler has nothing to disclose. Conflict of interest: K.W. Miskowiak reports personal feels from Lundbeck outside the submitted work. Conflict of interest: K. Kunalan has nothing to disclose. Conflict of interest: A. Victor has nothing to disclose. Conflict of interest: L. Pedersen has nothing to disclose. Conflict of interest: H.F. Andreassen has nothing to disclose. Conflict of interest: B.J. Jørgensen has nothing to disclose. Conflict of interest: H. Heebøll has nothing to disclose. Conflict of interest: M.B. Andersen has nothing to disclose. Conflict of interest: L. Marner has nothing to disclose. Conflict of interest: C. Hædersdal has nothing to disclose. Conflict of interest: H. Hansen has nothing to disclose. Conflict of interest: S. Ditlev has nothing to disclose. Conflict of interest: C. Porsbjerg has nothing to disclose. Conflict of interest: T.S. Lapperre has nothing to disclose.
Références
J Affect Disord. 2015 Nov 15;187:10-9
pubmed: 26301477
Eur Respir J. 2015 Apr;45(4):863-6
pubmed: 25829426
Br J Clin Psychol. 1982 Feb;21(1):1-16
pubmed: 7126941
N Engl J Med. 2020 Jul 9;383(2):120-128
pubmed: 32437596
Chest. 2005 Oct;128(4):2247-61
pubmed: 16236881
Respir Med. 2015 Jul;109(7):897-903
pubmed: 26028484
Eur Respir J. 2021 Apr 29;57(4):
pubmed: 33303540
JAMA. 2020 Aug 11;324(6):603-605
pubmed: 32644129
Int J Public Health. 2013 Dec;58(6):949-53
pubmed: 23974352
Eur Respir J. 2021 Apr 29;57(4):
pubmed: 33419891
Brain Behav Immun. 2020 Jul;87:115-119
pubmed: 32360439
Respir Res. 2020 Jun 29;21(1):163
pubmed: 32600344
N Engl J Med. 2020 May 14;382(20):e60
pubmed: 32343504
BMC Infect Dis. 2021 Jan 9;21(1):39
pubmed: 33421989
BMJ. 2020 Aug 3;370:m3001
pubmed: 32747332
Quant Imaging Med Surg. 2020 Sep;10(9):1852-1862
pubmed: 32879862
Arch Iran Med. 2020 Apr 01;23(4):268-271
pubmed: 32271601
Ther Adv Respir Dis. 2018 Jan-Dec;12:1753466618793028
pubmed: 30091679
BMJ. 2020 Aug 11;370:m3026
pubmed: 32784198
Eur Respir J. 2020 Jul 2;56(1):
pubmed: 32398306
Eur Respir J. 2020 Oct 15;56(4):
pubmed: 32764112
EClinicalMedicine. 2021 Sep;39:101044
pubmed: 34316551
Clin Nutr. 2008 Aug;27(4):601-7
pubmed: 18547686
Lancet. 2021 Jan 16;397(10270):220-232
pubmed: 33428867
Eur Respir J. 2021 Jul 22;58(1):
pubmed: 33574077
J Alzheimers Dis Rep. 2020 Jun 16;4(1):217-221
pubmed: 32715280
Curr Cardiol Rep. 2020 Apr 21;22(5):32
pubmed: 32318865
Clin Infect Dis. 2021 Sep 7;73(5):e1089-e1098
pubmed: 33220049
Postgrad Med J. 2007 Nov;83(985):675-82
pubmed: 17989266
Int J Chron Obstruct Pulmon Dis. 2015 Nov 11;10:2423-30
pubmed: 26648705
Respirology. 2010 Apr;15(3):543-50
pubmed: 20337995
Respir Res. 2017 Jun 2;18(1):112
pubmed: 28578705
Eur Respir J. 2021 Sep 16;58(3):
pubmed: 33574080
ERJ Open Res. 2020 Oct 26;6(4):
pubmed: 33257910
Thorax. 2020 Nov;75(11):1009-1016
pubmed: 32839287
Sci Rep. 2021 Aug 9;11(1):16144
pubmed: 34373540